The Association between Single Nucleotide Polymorphisms of Sclerostin (SOST) Gene, Bone Mineral Density and Circulating Osteoprotegerin (OPG)
- Author:
Hee Jun LEE
1
;
Hoon KIM
;
Seung Yup KU
;
Seok Hyun KIM
;
Young Min CHOI
;
Jung Gu KIM
Author Information
1. Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Korea. kimjg@snu.ac.kr
- Publication Type:Original Article
- Keywords:
BMD;
Genetic polymorphism;
Hormone therapy;
SOST
- MeSH:
Absorptiometry, Photon;
Alkaline Phosphatase;
Biomarkers;
Bone Density;
Collagen;
Enzyme-Linked Immunosorbent Assay;
Female;
Femur Neck;
Genotype;
Humans;
NF-kappa B;
Osteocalcin;
Osteoporosis;
Osteoprotegerin;
Peptide Fragments;
Polymorphism, Genetic;
Polymorphism, Single Nucleotide;
Prevalence;
Receptor Activator of Nuclear Factor-kappa B;
Sequence Analysis, DNA;
Spine
- From:Journal of Korean Society of Osteoporosis
2012;10(3):119-128
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: To investigate the relationship between polymorphisms of sclerostin (SOST) gene and bone mineral density (BMD) in postmenopausal Korean women. MATERIALS AND METHODS: The SOST rs865429 (g.5942C>T), rs17882143 (c.28G>A), rs10534024 (-1396TCC/Del) polymorphisms were analyzed by Taqman assay and direct DNA sequencing in 399 postmenopausal Korean women. Serum CrossLaps (CTX), bone alkaline phosphatase (BAP), osteocalcin, osteoprotegerin (OPG) and soluble receptor activator of NF-kB ligand (sRANKL) were measured by enzyme linked immunosorbent assay. The BMD at the lumbar spine (LS) and femoral neck (FN) were determined by dual energy X-ray absorptiometry, and in 311 postmenopausal women receiving hormone therapy (HT) BMD was also measured after HT of 1 year.
